Zepbound® Providers &
Prescriptions in Virginia
Verified Zepbound providers across Virginia. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]
Find a Zepbound provider in Virginia.
Every entry is checked against the NPI registry and the Virginia medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.
How a prescription works in Virginia.
You don’t have to leave Virginia to start. Because tirzepatide isn't a controlled substance, a Virginia-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you — or you can see one of the 32 local providers below in person. What you pay depends on your plan, not your zip code.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Virginia’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults — same molecule as Ozempic, higher dose.
Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo — among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]
What the trials actually showed.
We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%) — more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Zepbound (tirzepatide) prescribers and clinics — ordered by availability, never by who pays us.
Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover — ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.
They are the same molecule — tirzepatide, made by Eli Lilly — with different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]